AZD 8186

Drug Profile

AZD 8186

Alternative Names: AZD-8186

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 14 Jul 2017 National Cancer Institute plans a phase I trial for Cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Combination therapy) in USA in March 2018 (NCT03218826)
  • 02 Jun 2017 Efficacy, safety and pharmacokinetics data from a phase I trial in Solid tumour presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 29 Nov 2016 Interim efficacy, adverse event, pharmacokinetic and pharmacodynamic data from a phase I trial in Prostate cancer, Non-small cell lung cancer, Breast cancer and Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top